3 active not recruiting, 1 completed. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 2 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow ML Bio Solutions, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-Label Extension Study of BBP-418 (Ribitol) for LGMD2I/R9 BBP-418 (ribitol) - Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) | Phase 3 | Active not recruiting | ML Bio Solutions, Inc. | 107 | 2026-06-05 | 2026-07-02 |
| Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I) BBP-418 (ribitol), Placebo - Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) | Phase 3 | Active not recruiting | ML Bio Solutions, Inc. | 112 | 2023-05-31 | 2026-09-09 |
| Study of BBP-418 in Patients With LGMD2I BBP-418 - LGMD2I | Phase 2 | Active not recruiting | ML Bio Solutions, Inc. | 14 | 2021-02-18 | 2026-07-21 |
| Biomarker Development in LGMD2i Muscular Dystrophies, Limb Girdle Muscular Dystrophy | Completed | ML Bio Solutions, Inc. | 101 | 2019-12-01 | 2023-03-29 |
Muscular Dystrophy, Limb-Girdle, Type 2I (4) · Muscular Dystrophies, Limb-Girdle (2) · Muscular Dystrophies (1)
Ribitol (2)
United States (4) · Denmark (3) · Australia (2) · Germany (2) · Italy (2) · Netherlands (2) · Norway (2) · United Kingdom (2)
Amy Harper, MD (1) · Nicholas E Johnson, MD (1)